Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$0.92
-2.3%
$0.78
$0.47
$9.60
$4.68M1.28238,987 shs62,206 shs
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
$1.38
-1.4%
$2.26
$0.97
$22.40
$4.75M0.31137,882 shs56,797 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$2.87
$3.24
$1.75
$9.37
$4.71M1.38806,313 shs12,879 shs
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
$0.00
-18.5%
$0.00
$0.00
$0.42
$1.21M2.25511,766 shs510,020 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
0.00%+0.79%+13.31%+76.94%+395.48%
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
0.00%-3.50%-31.51%-57.01%-91.40%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00%-5.59%-16.57%+31.05%+1,252.50%
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
0.00%0.00%+29.41%+214.29%-76.84%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
0.1524 of 5 stars
0.03.00.00.00.00.00.6
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
3.3269 of 5 stars
3.35.00.00.01.60.01.3
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.8909 of 5 stars
0.05.00.00.03.30.00.0
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
2.00
HoldN/AN/A
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
2.50
Moderate Buy$14.00914.49% Upside
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/A$4.43 per shareN/A
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
$890K5.33N/AN/A$2.61 per share0.53
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$14.29M0.33N/AN/A$2.73 per share1.05
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
$62.84M0.02N/AN/A($0.05) per share-0.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
-$22.94M-$3.86N/AN/AN/A-123.06%-94.28%N/A
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
-$21.65M-$65.60N/AN/AN/AN/AN/AN/A7/1/2025 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.46M-$3.10N/AN/AN/A-24.23%-58.73%-21.05%8/6/2025 (Estimated)
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
-$572.84MN/A0.00N/AN/AN/AN/AN/A

Latest SRNEQ, MYNZ, SNOA, and MTNB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/1/2025N/A
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
-$2.80N/AN/AN/AN/AN/A
6/17/2025Q4 2025
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.73-$0.15+$0.58-$0.48$4.44 million$3.75 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/AN/A
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/A
5.53
5.53
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
0.14
1.32
1.26
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.09
2.38
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
11.77%
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
N/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
0.02%
CompanyEmployeesShares OutstandingFree FloatOptionable
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
305.09 million4.60 millionN/A
Mainz Biomed NV stock logo
MYNZ
Mainz Biomed
303.44 millionN/ANot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.64 million1.58 millionNot Optionable
Sorrento Therapeutics, Inc. stock logo
SRNEQ
Sorrento Therapeutics
800551.28 million536.95 millionNot Optionable

Recent News About These Companies

Sorrento, Naples, Italy Weather Conditionsstar_ratehome
Sorrento Announces New Board Member

New MarketBeat Followers Over Time

Media Sentiment Over Time

Matinas Biopharma stock logo

Matinas Biopharma NYSE:MTNB

$0.92 -0.02 (-2.32%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$0.92 +0.00 (+0.10%)
As of 04:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Mainz Biomed stock logo

Mainz Biomed NASDAQ:MYNZ

$1.38 -0.02 (-1.43%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$0.97 -0.41 (-29.86%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$2.87 0.00 (0.00%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$4.42 +1.55 (+54.01%)
As of 05:21 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Sorrento Therapeutics stock logo

Sorrento Therapeutics OTCMKTS:SRNEQ

$0.0022 0.00 (-18.52%)
As of 06/27/2025

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.